Press "Enter" to skip to content

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial – The Lancet

admin 0

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial  The Lancet

Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and …

“ovarian cancer” – Google News

(Visited 10 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *